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Background: Hemophagocytic lymphohistiocytosis in adults is often secundary to an infection or a neoplasm. In
this last case, T cell lymphomas are the most frequent causes. Hemophagocytic lymphohistiocytosis secundary to a
B cell lymphoma has been rarely reported.
Case presentation: We describe a case of a hemophagocytic lymphohistiocytosis complicating a T-cell rich B-cell
lymphoma treated with conventionnal chemotherapy leading to a complete remission.
Conclusion: Prompt etiologic diagnosis and treatment of hemophagocytic lymphohistiocytosis leads to satisfactory
outcome.Background
Hemophagocytic lymphohistiocytosis (HLH) is a rare
and often fatal inflammatory disease. It is either primary
or secondary to inflammatory diseases, infections or ma-
lignancies. In the latter case, T phenotype non-Hodgkin
lymphoma (NHL) is the most common cause [1]. The
association with B lymphomas is rare [2]. In this situ-
ation, lymphoma chemotherapy treatment should be
initiated promptly to control HLH. T-cell rich B-cell
lymphoma is a rare entity representing 1 to 3 % of dif-
fuse large B-cell NHL [3].
We describe in this paper the case of a patient with a
hemophagocytic lymphohistiocytosis revealing a T cells
rich B-cell NHL.Case presentation
A 52-year-old male patient without any significant med-
ical history was admitted to our department for febrile
bicytopenia. He reported an anemic syndrome as he had
been complaining of fatigue and exertional dyspnea for
8 months before his admission. Fever and significant
weight loss were also reported over the last month before
his admission.* Correspondence: mahtatelmehdi@gmail.com
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splenomegaly (4 cm below left costal margin), right axil-
lary and bilateral inguinal lymphadenopathies (the most
voluminous measured 3 cm of diameter).
Laboratory tests found haemoglobin level at 70 g/L
(range 130–165 G/L) with a mean corpuscular volume
of 80 fl (range 80–96 fl), leukocytes at 2.9 G/L (range 4–
10 G/L) (neutrophils 1.5 G/L and lymphocytes 0.9 G/L).
Platelets were 39 G/L (range 150–400 G/L). Reticulocyte
count was 43 G/L (50–120 G/L). Biochemical tests
showed an increased LDH rate at 508 IU/L (upper limit:
192 UI/L) and serum ferritin at 4456 ng/mL (range 23–
336 ng/mL). Triglycerides were 225 mg/dL (range 101–
150 mg/dL). Fibrinogen was also raised at 6,72 g/L
(range 1,5–4 g/L). Infectious tests, including EBV PCR
screening, were negative.
Hemophagocytic lymphohistiocytosis was strongly sus-
pected according to Henter criteria [4] and a bone mar-
row aspiration was performed showing a rich marrow
with hemophagocytosis (Fig. 1) without lymphomatous
infiltration. Thus, the diagnosis of hemophagocytic lym-
phohistiocytosis was confirmed.
The patient received a pulse of steroids (methylpred-
nisolone 25 mg/kg/day for 3 days followed by prednisol-
one 2 mg/kg/day) as well as red blood cells and platelets
supportive transfusion.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Marrow aspirate smear showing examples of hemophagocytosis, May Grunwald Giemsa stain, × 1000
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node parenchyma which overall architecture is erased by
diffuse immunoblastic large cells proliferation. These
scattered large neoplastic cells are present on a back-
ground rich in histiocytes and small lymphocytes (Fig. 2).
Immunohistochemistry studies showed expression of
CD20 in the large neoplastic cells (Fig. 3) and CD3 in
the small T cells (Fig. 4). CD30, CD15 and EBV stains
were negative.
Computed tomography (CT) scan of the chest, abdo-
men and pelvis showed enlarged lymph nodes on both
sides of diaphragm and a 20 cm large spleen with mul-
tiple hypodensities, likely to be related to infarcts (Fig. 5).
A bone marrow biopsy was also performed and showed
no infiltration.Fig. 2 Lymphadenopathy biopsy showing diffuse lymphohystiocytic
infiltration the normal architecture with scattered large atypical cells
(Arrows), H&E stain, × 400Therefore, this case was diagnosed as T-cell rich B-cell
Hodgkin lymphoma stage III B (Ann Arbor staging)
complicated by a HLH.
The patient was treated with chemotherapy combining
rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone (R-CHOP). He received eight 21-day cy-
cles associated to 4 injections of prophylactic intrathecal
chemotherapy (methotrexate, cytarabine, methylprednis-
olone). The interim and the end of treatment revalua-
tions showed complete remission with normalization of
initially abnormal biological parameters.
After 10 months of follow-up, the patient presented
with axillar lymph nodes without general symptoms.
The biopsy of the lymph nodes showed the same aspect
as at the diagnosis. The patient is now undergoing sal-
vage therapy by Rituximab, dexamethasone, ifosfamide,
carboplatin and etoposide (R-DICE) regimen. It will beFig. 3 CD20 immunostain highlights large neoplastic B cells, × 400
Fig. 4 CD3 immunostain marking small lymphocytes × 1000
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transplantation.Discussion
HLH is the result of a secondary immune response
to stimuli which regulation is no longer controlled
by the natural killer lymphocytes (NK-L) [5]. In fa-
miliar cases, the major mutations affect granule-
mediated cytotoxicity pathways. The cytotoxicity
defect of the NK lymphocytes is the main patho-
physiological signature of HLH [6]. This promotesFig. 5 CT scan abdomen showing a 20 cm large spleen with
multiple hypodensities (infarcts)proliferation and continuous activation of antigen
presenting cells with a hyper-secretion of cytokines
and chemokines, causing a “cytokine storm” [7]. In-
deed, activated T lymphocytes (TL) secrete inter-
feron gamma in large amounts inducing expansion
and activation of CD8 T cells, histiocytes and
macrophages. These cells infiltrate various organs,
including the hematopoïetic organs [1]. The “cyto-
kine storm” is responsible for clinical features and
laboratory findings of multi-organ failure as seen in
the HLH. Interleukin (IL) 1, IL-6 and tumor necrosis
factor alpha are responsible for fever. Hypertriglyc-
eridemia is secondary to the inhibition of lipoprotein
lipase and stimulation of the synthesis of triglycer-
ides by INFγ et TNFa [8]. These cytokines also
inhibit normal hematopoiesis inducing cytopenias.
Hyperferritinaemia and hypofibrinogenemia are
secondary to the continuous activation of macro-
phages [5].
The diagnosis of HLH is based on the combination
of clinical and laboratory criteria (Table 1) [4]. Clini-
cians must think about it in the case of fever of
unknown origin. This syndrome can be hereditary or
acquired. In the latter case, it is most often associated
with infections (49 %); infection with Epstein Barr
Virus (EBV) being the most common cause. It is sec-
ondary to neoplasia in up to 27 % of cases and
associated with rheumatic diseases in 7 % and im-
munodeficiencies in 6 % of cases [5]. When HLH is
secondary to malignancies, it is most often associated
with T or NK phenotype lymphoma or leukemia.
However associations to anaplastic lymphomas, acute
B lineage lymphoblastic or myeloblastic leukemias, as
well as solid tumors have been reported [5]. The as-
sociation with NHL phenotype B is rarely reported;
often described in older patients with less directTable 1 Diagnostic criteria for HLH [4]
≥ five of the eight criteria listed below:
Fever
Splenomegaly
Cytopenias (affecting at least two of three lineages in the peripheral
blood):
• Hemoglobin < 9 g/dl
• Platelets < 100 G/mm3
• Neutrophils <1 G/mm3
Hypertriglyceridemia (fasting, 265 mg/100 ml) and/or
hypofibrinogenemia (150 mg/100 ml)
Hemophagocytosis in bone marrow, spleen or lymph nodes
Ferritin≥ 500 ng/ml
Low or absent Natural Killer cell activity
Soluble IL-2 receptor≥ 2400 U/ml
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oma secondary HLH [2]. Indeed, our patient had no
bone marrow infiltration. In the case HLH in adults,
a thoracic and abdominal CT scan and a bone mar-
row biopsy looking for a lymphomatous infiltration
can be helpful to find a possible underlying malig-
nancy [1]. The peculiarity of our case is the associ-
ation of HLH to a particular histological presentation
of B-cell NHL. The T-cell rich B-cell lymphoma is a
rare histological form accounting for 1–3 % of
DLBCL. Histologically, it is characterized by the
presence of less than 10 % large B cells in a cellular
background made of small cytotoxic lymphocytes and
histiocytes [3]. The main differential diagnosis of this
entity is nodular lymphocyte-predominant Hodgkin
lymphoma. Immunohistochemistry can rule out this
diagnosis with the negativity of CD30 and CD15 on
large cells, and a clear-cut CD20 positivity on the
large cells [3]. The combination of a T-cell rich B-cell
lymphoma and HLH has already been described
(Table 2). Mitterer et al reported a case of T cells
rich B-cell NHL (TCRBCL) with HLH and concomi-
tant EBV reactivation, but the malignant cells did not
express EBV oncoprotein LMP-1 and the EBVTable 2 Clinical, biological, therapeutic and evolution features of pr
Case Sex Age Clinical features Laboratory findings Pa
Mitterrer
et al. [9]
































































LDH lacticodeshydrogenase, R-EPOCH Rituximab, etoposide, prednisone, vincristine,
autologous hematopoietic stem cell transplantation, TCRBCL T-cell rich B-cell lymph
rubicin, bleomycin, vincristine, PCR polymerase chain reactioninfection was probably related to the immunodefi-
ciency induced by the HLH syndrome in that case
[9]. In our case there was no evidence of ongoing
EBV infection. The link between HLH and TCRBCL
is not accidental, in fact the study of the gene expres-
sion profile of T-cell rich B-cell lymphoma showed tolero-
genic immune response signatures of the host explaining
the aggressive nature of this type of lymphoma and the as-
sociated immune reactions [10]. It was also demonstrated
that the immunomodulatory molecule programmed death
ligand 1 (PD-L1) is expressed by the tumor cells and the
histiocytes in T-cell rich B NHL and may inhibit T-cell
immunity [11].Conclusion
Hemophagocytic lymphohistiocytosis is a diagnostic
and therapeutic emergency. The main underlying
causes of this syndrome in adults are either infec-
tious or T lymphomatous proliferations. The associ-
ation with T cells rich B lymphoma is rarely
described. A prompt antilymphomatous chemother-
apy should be initiated to control the life-threatening
HLH.eviously reported cases of TCRBCL associated HLH














































cyclophosphamide and doxorubicine, CR complete remission, AHSCT
oma, MOPP-ABV mechlorethamine, vincristine, procarbazine, prednisone/doxo-
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